1/23
05:09 am
vor
Vor Biopharma (NASDAQ:VOR) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Medium
Report
Vor Biopharma (NASDAQ:VOR) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
1/9
08:02 am
vor
Vor Biopharma (NASDAQ:VOR) is now covered by analysts at Citigroup Inc.. They set a "buy" rating and a $50.00 price target on the stock.
Low
Report
Vor Biopharma (NASDAQ:VOR) is now covered by analysts at Citigroup Inc.. They set a "buy" rating and a $50.00 price target on the stock.
1/6
08:00 am
vor
Vor Bio to Participate in the 44th Annual J.P. Morgan Healthcare Conference
Medium
Report
Vor Bio to Participate in the 44th Annual J.P. Morgan Healthcare Conference
12/23
04:01 pm
vor
Vor Bio Appoints RA Capital’s Andrew Levin, M.D., Ph.D., and Forbion’s Wouter Joustra to Board of Directors
Medium
Report
Vor Bio Appoints RA Capital’s Andrew Levin, M.D., Ph.D., and Forbion’s Wouter Joustra to Board of Directors
12/19
11:38 am
vor
Vor Biopharma (NASDAQ:VOR) had its price target lowered by analysts at JPMorgan Chase & Co. from $43.00 to $40.00. They now have an "overweight" rating on the stock.
Medium
Report
Vor Biopharma (NASDAQ:VOR) had its price target lowered by analysts at JPMorgan Chase & Co. from $43.00 to $40.00. They now have an "overweight" rating on the stock.
12/17
10:22 am
vor
Vor Biopharma (NASDAQ:VOR) is now covered by analysts at TD Cowen. They set a "buy" rating on the stock.
Medium
Report
Vor Biopharma (NASDAQ:VOR) is now covered by analysts at TD Cowen. They set a "buy" rating on the stock.
12/15
08:00 am
vor
Vor Bio Announces $150 Million Private Placement
Medium
Report
Vor Bio Announces $150 Million Private Placement
12/10
11:24 am
vor
Vor Biopharma (VOR): Valuation Check After Positive Telitacicept Phase 3 Data and Upbeat JPMorgan Coverage [Yahoo! Finance]
Low
Report
Vor Biopharma (VOR): Valuation Check After Positive Telitacicept Phase 3 Data and Upbeat JPMorgan Coverage [Yahoo! Finance]
12/9
08:07 am
vor
Vor Biopharma (NASDAQ:VOR) is now covered by analysts at JPMorgan Chase & Co.. They set an "overweight" rating and a $43.00 price target on the stock.
Medium
Report
Vor Biopharma (NASDAQ:VOR) is now covered by analysts at JPMorgan Chase & Co.. They set an "overweight" rating and a $43.00 price target on the stock.
11/25
09:06 am
vor
Vor Biopharma (NASDAQ:VOR) had its "neutral" rating reaffirmed by analysts at Wedbush. They now have a $9.00 price target on the stock.
Medium
Report
Vor Biopharma (NASDAQ:VOR) had its "neutral" rating reaffirmed by analysts at Wedbush. They now have a $9.00 price target on the stock.
11/14
08:09 am
vor
Vor Biopharma (NASDAQ:VOR) had its price target lowered by analysts at HC Wainwright from $55.00 to $32.00. They now have a "buy" rating on the stock.
Low
Report
Vor Biopharma (NASDAQ:VOR) had its price target lowered by analysts at HC Wainwright from $55.00 to $32.00. They now have a "buy" rating on the stock.
11/13
07:23 am
vor
Vor Biopharma (NASDAQ:VOR) was upgraded by analysts at Zacks Research from a "strong sell" rating to a "hold" rating.
Medium
Report
Vor Biopharma (NASDAQ:VOR) was upgraded by analysts at Zacks Research from a "strong sell" rating to a "hold" rating.
11/10
09:56 pm
vor
Vor Bio Announces Pricing of Public Offering of $100 Million of Common Stock
High
Report
Vor Bio Announces Pricing of Public Offering of $100 Million of Common Stock
11/10
04:01 pm
vor
Vor Bio Announces Proposed Public Offering of $100 Million of Common Stock
High
Report
Vor Bio Announces Proposed Public Offering of $100 Million of Common Stock
11/8
11:45 am
vor
Telitacicept Achieved Primary Endpoint of Reducing Proteinuria in Stage A of a Phase 3 Clinical Study for IgA Nephropathy in China
Low
Report
Telitacicept Achieved Primary Endpoint of Reducing Proteinuria in Stage A of a Phase 3 Clinical Study for IgA Nephropathy in China
11/7
08:00 am
vor
Vor Bio to Participate in Upcoming Investor Conferences
Low
Report
Vor Bio to Participate in Upcoming Investor Conferences